EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Ref‐1 redox activity regulates retinal neovascularization by modulating transcriptional activation of HIF ‐1α

Gabriella D Hartman iD, Anbukkarasi Muniyandi iD, Kamakshi Sishtla iD, Eyram K Kpenu iD, William P Miller iD, Bryan A Kaplan iD, Leo A Kim iD, Sheng Liu iD, Jun Wan iD, Xiaoping Qi iD, Michael E Boulton iD, Mark R Kelley iD und 1 weitere

The FASEB Journal · 2025

DOI: 10.1096/fj.202401989rr ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Gabriella D Hartman und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Retinal Neovascularization, Hypoxia-Inducible Factor 1, alpha Subunit, DNA-(Apurinic or Apyrimidinic Site) Lyase, Transcriptional Activation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: HHS | NIH | National Eye Institute (NEI), Tom Wood Lexus Foundation, HHS | NIH | National Cancer Institute (NCI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Retinal neovascularization impairs visual function and is a hallmark of several neovascular eye diseases, including retinopathy of prematurity (ROP) and proliferative diabetic retinopathy (PDR). Current treatments include intravitreal injections of anti‐vascular endothelial growth factor (VEGF) biologics, but these therapeutics are often accompanied by high treatment burden and resistance to therapy. Prior studies indicate that APE1/Ref‐1, a multifunctional protein with both endonuclease (APE1) and redox‐mediated transcriptional regulatory activity (Ref‐1), activates multiple pro‐angiogenic and pro‐inflammatory signaling pathways by chemically reducing key cysteine residues in transcription factors, thereby activating them. Here, we investigated the previously unexplored role of Ref‐1 in retinal neovascularization. We demonstrate that Ref‐1 is highly expressed in endothelial cells in human PDR and in the oxygen‐induced retinopathy (OIR) mouse model of retinal neovascularization. Ref‐1 is also highly expressed in microglia and astrocytes in OIR. A small molecule Ref‐1 redox inhibitor, APX2009, decreased retinal neovascularization in OIR after systemic delivery. In vitro, hypoxic endothelial cells did not exhibit upregulation of Ref‐1 but rather increased Ref‐1 nuclear localization. APX2009 decreased hypoxic endothelial cell proliferation and HIF‐1α transcriptional activation. Thus, Ref‐1 redox activity may be a novel therapeutic target for the treatment of retinal neovascularization, making APX2009 a promising systemic therapeutic approach for the treatment of vascular retinopathies such as ROP and PDR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Retinal NeovascularizationHypoxia-Inducible Factor 1, alpha SubunitDNA-(Apurinic or Apyrimidinic Site) LyaseTranscriptional ActivationAnimalsMiceHumansOxidation-ReductionDiabetic RetinopathyMice, Inbred C57BLRetinopathy of Prematurity

Stichwörter der Autor:innen

APE1/Ref‐1hypoxia‐inducible factoroxygen‐induced retinopathyredox regulationretinal neovascularization

Substanzen

Hypoxia-Inducible Factor 1, alpha SubunitDNA-(Apurinic or Apyrimidinic Site) LyaseAPEX1 protein, humanHIF1A protein, humanApex1 protein, mouseHif1a protein, mouse

Autor:innen und Institutionen

  • Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
  • Herman B Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA.

ORCID-Profile: Gabriella D Hartman, Anbukkarasi Muniyandi, Kamakshi Sishtla, Eyram K Kpenu, William P Miller, Bryan A Kaplan, Leo A Kim, Sheng Liu, Jun Wan, Xiaoping Qi, Michael E Boulton, Mark R Kelley, Timothy W Corson

Förderung

  • HHS | NIH | National Eye Institute (NEI)
  • Tom Wood Lexus Foundation
  • HHS | NIH | National Cancer Institute (NCI)
  • NCI NIH HHS
  • Research to Prevent Blindness (RPB)
  • Riley Children's Foundation (RCF)
  • NEI NIH HHS
  • Canada Foundation for Innovation (CFI)

Zitieren

APA

Hartman, G. D., Muniyandi, A., Sishtla, K., Kpenu, E. K., Miller, W. P., Kaplan, B. A., Kim, L. A., Liu, S., Wan, J., Qi, X., Boulton, M. E., Kelley, M. R., & Corson, T. W. (2025). Ref‐1 redox activity regulates retinal neovascularization by modulating transcriptional activation of HIF ‐1α. The FASEB Journal. https://doi.org/10.1096/fj.202401989rr

Vancouver

Hartman GD, Muniyandi A, Sishtla K, Kpenu EK, Miller WP, Kaplan BA, et al. Ref‐1 redox activity regulates retinal neovascularization by modulating transcriptional activation of HIF ‐1α. The FASEB Journal. 2025. doi:10.1096/fj.202401989rr

BibTeX
@article{Hartman2025,
  author = {Hartman, Gabriella D and Muniyandi, Anbukkarasi and Sishtla, Kamakshi and Kpenu, Eyram K and Miller, William P and Kaplan, Bryan A and Kim, Leo A and Liu, Sheng and Wan, Jun and Qi, Xiaoping and Boulton, Michael E and Kelley, Mark R and Corson, Timothy W},
  title = {Ref‐1 redox activity regulates retinal neovascularization by modulating transcriptional activation of HIF ‐1α},
  journal = {The FASEB Journal},
  year = {2025},
  doi = {10.1096/fj.202401989rr}
}
Kostenlos starten →